Nvidia Options Price in $280 Billion Earnings Swing 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SK Hynix Shares Fall as Workers Reject Wage Deal 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
PARSIPPANY, N.J., May 01, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences:
- Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET
- Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET)
A live audio webcast of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcasts will be archived on the Pacira website for two weeks following the presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti (973) 254-4387 [email protected]
